Lercanidipine + Valsartan + Nicorandil + Doxazosin + Moxonidin + Pindolol + Amiloride, hydrochlorothiazide
Pre-clinicalTerminated 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Microvascular Angina
Conditions
Microvascular Angina, Hypertension
Trial Timeline
Jan 1, 2007 → Dec 1, 2008
NCT ID
NCT00424801About Lercanidipine + Valsartan + Nicorandil + Doxazosin + Moxonidin + Pindolol + Amiloride, hydrochlorothiazide
Lercanidipine + Valsartan + Nicorandil + Doxazosin + Moxonidin + Pindolol + Amiloride, hydrochlorothiazide is a pre-clinical stage product being developed by Novartis for Microvascular Angina. The current trial status is terminated. This product is registered under clinical trial identifier NCT00424801. Target conditions include Microvascular Angina, Hypertension.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00424801 | Pre-clinical | Terminated |
Competing Products
7 competing products in Microvascular Angina
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zibotentan + Placebo oral tablet | AstraZeneca | Phase 2 | 52 |
| Ranolazine + Placebo | Gilead Sciences | Approved | 84 |
| Ranolazine + Placebo | Gilead Sciences | Phase 2 | 51 |
| Temanogrel + Placebo | Pfizer | Phase 2 | 51 |
| SAR247799 + Placebo + Sildenafil + Acetylcholine | Sanofi | Phase 1 | 32 |
| SAR407899 + Placebo + Adenosine + Regadenoson + 13N-ammonia + 82Rubidium | Sanofi | Phase 2 | 51 |
| Felzartamab + Placebo | Biogen | Phase 2 | 49 |